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ABSTRACT 
The World Health Organization (WHO) notes high-rates of resistance among bacteria associated with common illness in all the WHO-regions - 
both hospital-acquired and community-acquired (WHO 2014). An estimated 2 million cases of antibiotic-resistance are reported in the US 
annually, causing 23,000 deaths. With reference to such, the US CDC states that about 30% of the total-annual 150 million prescriptions for 
antibiotics is not justified. There is a need for greater prudence in the use involving joint-efforts in surveillance, public health awareness 
additionally, and in formulating clear policies on procurement and prudent use.  
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INTRODUCTION 
Antibiotics, in the practice of modern medicine, have been 
instrumental in reducing morbidity and mortality from 
infectious-diseases. But here, decades of advancements 
stand threatened by the emergence of antibiotic-resistance. 
The cause of antibiotic-resistance is multi-factorial. But, 
increased consumption in the community not only produces 
greater resistance at the individual patient-level, also at the 
community, country, and regional levels – and, such could 
harm individual patients (Bell BG et al 2014). 
The cost to the 'fitness' of an organism is its ability to 
replicate and survive in a competitive environment. For 
instance if antibiotic resistance could be acquired by bacteria 
without any "fitness cost" all the human bacteria (as well as 
all the environmental ones) would be pan-resistant already 
(Melynk AH et al 2015). 
The World Health Organization (WHO) notes high-rates of 
resistance among bacteria associated with common illness in 
all the WHO-regions - both hospital-acquired and 
community-acquired (WHO 2014). 
An estimated 2 million cases of antibiotic-resistance are 
reported in the US annually, causing 23,000 deaths. With 
reference to such, the US CDC states that about 30% of the 
total-annual 150 million prescriptions for antibiotics is not 
justified. 
The situation is the same in Malaysia - a steady increase in 
antibiotic-resistance involving common organisms has been 
observed. 
Alvarez-Uria G et al (2018) using mixed linear models and 
inverse probability weighting methods concluded that third-
generation cephalosporins and carbapenems could be 
ineffective against a sizeable proportion of infections by E. 
coli and K. pneumoniae in most parts of the world by 2030. 
There is a need for greater prudence in the use involving 
joint-efforts in surveillance, public health awareness 
additionally, and in formulating clear policies on 
procurement and prudent use.  
PATTERNS OF ANTIBIOTIC-RESISTANCE 
Escherichia coli – resistance to third-generation 
cephalosporins and to fluoroquinolones 
E. coli in the intestine in humans and animals is part of the 
normal flora.  
Alvarez-Uria G et al (2018) estimated the prevalence of 
antimicrobial resistance (AMR) in 2015 was 64.5% (95% CI 
42–87%) for third-generation cephalosporin-resistant 
(3GCR) Escherichia coli, and 5.8% (95% CI 1.8–9.7%) for 
carbapenem-resistant (CR) E.coli. The projected AMR 
prevalence in 2030 was 77% (95% CI 55–99.1%) for 3GCR E. 
coli, and 11.8% (95% CI 3.7–19.9%) for CR E. coli. 
It is:  
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• the commonest cause of community and hospital-acquired 
urinary tract infections (including kidney-infections);  
• the commonest cause of bloodstream-infection at all ages;  
• commonly the cause of intra-abdominal infections such as 
peritonitis, besides skin and soft tissue infections caused by 
multiple microorganisms;  
• a cause of meningitis in neonates; and  
• a leading causative-agent of foodborne-infections globally. 
Infections caused by such resistant-strains of E. coli carry a 
risk of poorer clinical-outcomes in patients and increasingly 
use up health-care resources. 
Summary: Public health implications of E coli resistance to 
third-generation cephalosporins 
Due to high-reported proportions of resistance to third-
generation cephalosporins treatment for severe infections by 
E. coli may need to be initiated with broader therapy (e.g. 
carbapenems) leading to higher costs and stimulus to the 
expansion of carbapenem-resistant strains.  
Summary: Public health implications of E coli resistance to 
fluoro-quinolones 
Quinolones are a widely-used groups of antibiotics in the 
treatment of urinary tract infections, of which E. coli is the 
commonest cause.  
Resistance to quinolones frequently means resistance to one 
of the last available oral-treatment options. 
Without availability of oral-treatment, treatment by injection 
becomes necessary – costing patients and the health-systems 
additionally. 
Klebsiella pneumoniae – resistance to third-generation 
cephalosporins and to carbapenems 
K. pneumoniae infections in hospitals are particularly 
common among vulnerable individuals such as pre-term 
infants besides patients with impaired immune systems, 
diabetes or alcohol-use disorders, and those receiving 
advanced medical-care. 
Alvarez-Uria G et al (2018) estimated the prevalence of 
antimicrobial resistance (AMR) in 2015 was 66.9% (95% CI 
47.1–86.8%) for 3GCR Klebsiella pneumoniae, and 23.4% 
(95% CI 7.4–39.4%) for CR K. pneumoniae. The projected 
AMR prevalence in 2030 was 58.2% (95% CI 50.2–66.1%) 
for 3GCR K. pneumoniae, and 52.8% (95% CI 16.3–89.3%) 
for CR K. pneumoniae. 
Urinary and respiratory tract infections are most common 
and bloodstream infections in neonates - a common cause of 
Gram-negative bloodstream infections. Globally, 
carbapenem-resistant K. pneumoniae infection is commonly 
seen. 
Summary: Public-health implications of resistant Klebsiella 
In the same manner as E. coli resistant to third-generation 
cephalosporins, the high proportions of cephalosporin-
resistance mean that treatment for severe K. pneumoniae 
infections frequently must rely on carbapenems (if 
available). 
 Such frequently leads to greater costs besides a risk of 
added expansion of carbapenem-resistant strains - which 
subsequently require treatment by those not so effective and 
not so widely available. 
 
Staphylococcus aureus – resistance to methicillin 
S. aureus causes a variety of infections - skin, soft tissue, 
bone and bloodstream infections. As a cause of postoperative 
wound infections it is the commonest.  
Some strains of S. aureus produce toxins which could cause 
toxic shock syndrome and food poisoning. 
Summary: Public health implications of methicillin-resistant 
staph aureus (MRSA) 
There is high-reported proportions of MRSA treatment for 
suspected or verified S. aureus infections in many countries. 
The implication of this is it could require additionally 
expensive second-line anti-bacterials. Such also includes 
prophylaxis in orthopaedic and many different surgical 
procedures. 
Koeck M et al (2019) found that the incidence of invasive 
MSSA (methicillin-sensitive) was more than twice that of 
invasive MRSA in two counties in Minnesota, USA. Invasive S. 
aureus infections were associated with a high case-fatality 
rate. Infection-types were similar except septic arthritis of 
bigger frequency noted among invasive MSSA cases and 
bacteremia and pneumonia of bigger frequency noted among 
invasive MRSA cases; these findings were consistent with 
those of various studies, although some previous studies 
found a bigger case-fatality rate for MRSA than MSSA 
infections, possibly attributable to the older age and co-
morbids among invasive MRSA case-patients. Although here 
case-patients with invasive MSSA had fewer co-morbids and 
were less likely to have pneumonia (a syndrome associated 
with poor outcomes) than case-patients with invasive MRSA, 
case-fatality rates were similar. 
Invasive MSSA-isolates were susceptible to bigger number of 
antimicrobial drugs and were genetically diverse than 
invasive MRSA isolates, consistent with results of previous 
reports. Penicillin-susceptibility was observed in 33% of 
invasive MSSA-isolates, which is considerably bigger than for 
previous studies of invasive and noninvasive MSSA isolates, 
and was seen for multiple strain types. 
The authors state that infection-control interventions have 
effectively decreased healthcare-associated invasive MRSA 
incidence. But, invasive S. aureus burden and mortality-rates 
remain a concern. Most invasive S. aureus disease was HACO 
(Health-care Associated; Community Onset) or Community 
Associated (CA), highlighting the need for preventing these 
community-onset infections through new approaches and 
infection prevention in settings outside acute care. 
Additionally, present-surveillance data could notify planning 
for future interventions, such as improved wound-care, 
enhanced infection prevention in nursing-homes and 
dialysis-centers, and added attention to chronic conditions 
and development of effective vaccines. 
Streptococcus pneumoniae – resistance (non-
susceptibility) to penicillin 
Globally, S. pneumoniae is the prime cause of community-
acquired pneumonia. Such pneumonia is among the main 
killers of children under 5 years of age. 
Besides mild infections, S. pneumoniae also causes invasive 
disease with high mortality such as meningitis. Among the 
bacterial causes of meningitis, S. pneumoniae carries the 
highest case-fatality rate. It is the most likely to leave 
survivors with permanent residual-symptoms. 
According to one estimate globally, S. pneumoniae caused 
about 826 000 deaths in children aged 1 - 59 months. 
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Kim L et al (2016) state that β-Lactam resistance is the 
hallmark of pneumococcal adaptability, requiring multiple 
independent recombination events that are traceable to non-
pneumococcal origins and stably perpetuated in multi-
resistant clonal-complexes. Pneumococcal-strains with 
elevated minimal inhibitory concentrations (MICs) of β-
lactams are most frequently resistant to additional 
antibiotics. Basic underlying mechanisms of most 
pneumococcal resistances have been identified, although 
new insights that increase understanding are continually 
provided. Although here all pneumococcal infections can be 
successfully treated with antibiotics, the existing choices are 
limited for some strains. Invasive pneumococcal disease data 
compiled during 1998 to 2013 through the population-based 
Active Bacterial Core surveillance program (U.S. population 
base of 30,600,000) demonstrated that targeting common 
capsular-serotypes with conjugate-vaccines (7-valent and 
13-valent vaccines implemented in 2000 and 2010, 
respectively) is extremely effective in reducing resistant-
infections. Nevertheless, resistant non-vaccine-serotype 
clones continue to emerge and expand. 
Summary: Public health implications of S. pneumoniae 
resistance (non-susceptibility) to penicillin 
When penicillin was first introduced, it very much changed 
the outcome for patients with pneumococcal pneumonia and 
accompanying bloodstream infection (which is common) 
from a case–fatality rate of about 90% to a survival-rate of 
about 90%. Resistance could reduce this advantage 
accorded. 
Besides, resistance-data also influences laboratory-diagnosis 
and treatment-guidelines for bloodstream-infections. 
Nontyphoidal Salmonella – resistance to 
fluoroquinolones 
Globally, bacteria of the genus Salmonella are a main cause of 
foodborne-illness.  
Salmonella is a zoonotic-pathogen, and the bacteria can be 
found in the intestines of numerous food-animals such as 
poultry and pigs. Infection is most frequently caused by 
consuming contaminated-water or food of animal-origin.  
Most Salmonella strains cause gastroenteritis. Certain strains 
are more invasive and typically cause Enteric fever - a largely 
serious-infection that brings about problems in treatment in 
numerous parts of the world due to antibiotic-resistance 
(ABR). 
Nontyphoidal Salmonella (NTS) comprise the bigger 
proportion of diarrhoeal-pathogens transmitted through the 
food-chain. One estimate indicates that there is found around 
94 million cases, resulting in 155 000 deaths, of NTS 
gastroenteritis each year globally. 
Kariuki S et al (2015) state that data from regions where 
enteric fever and iNTS (invasive) disease are endemic clearly 
show that ABR is a major public health problem, with MDR 
the norm and evidence of emerging resistance to 
cephalosporins and the fluoroquinolones that make these 
conditions untreatable in resource-limited settings. In 
addition to advocating for prudent use of existing 
antimicrobials where such are still effective, improved 
sanitation to reduce burden of illness and the wider 
introduction of WHO recommended typhoid vaccines and 
the acceleration of trials for novel typhoid, paratyphoid and 
iNTS vaccines are additional very useful steps that play a 
major role in management and control of these infections. 
Summary: Public health implications of Salmonella resistance 
to fluoroquinolones 
Infections caused by NTS are frequent but are usually self-
limiting. In severe cases, antibacterial-treatment may be 
required. 
 In multidrug-resistant Salmonella enterica serotype 
Typhimurium there is found a bigger risk of invasive-
infection, frequent hospitalization with bigger time-length of 
stay, prolonged-illness, and increased-risk of death in 
comparison with infections caused by susceptible strains. 
Shigella species – resistance to fluoroquinolones 
Shigella species are a main cause of diarrhoea and dysentery 
throughout the world. These bacteria are transmitted by 
fecal-oral route through contaminated food or water, or 
through person-to-person contact.  
Patients usually recover without complications within seven 
days, but shigellosis could become a life-threatening or fatal 
disease, particularly in children.  Globally, the annual 
number of Shigella-episodes is estimated around 165 million 
(of which more than 100 million is found in the developing 
world) causing in excess of one million deaths. 
Gebrekidan A et al (2015) in a study in Northern Ethiopia 
found that isolates of Shigella showed 100, 86.7 and 66.7 % 
resistance to ampicillin, amoxicillin and cotrimoxazole 
respectively. Low levels of resistance were observed for 
norfloxacin and ciprofloxacin (6.7 % each). Overall, 80 % of 
the isolates showed multidrug resistance. The researchers 
suggest that antibiotic-surveillance is needed to prevent 
added emergence of drug-resistant Shigella-strains.  
Provision of latrine, and supply of safe drinking-water to the 
community needed to be improved to reduce the disease-
burden. 
Summary: Public health implications of Shigella resistance to 
fluoroquinolones 
Antibacterial drugs have a proven outcome in the treatment 
of Shigella-infections, and frequently lifesaving. Emerging-
resistance has been reported as a concern in some countries. 
Neisseria gonorrhoeae – decreased susceptibility to 
third-generation cephalosporins 
Gonorrhoea is a sexually transmitted. An acute infection of 
the reproductive tract may be symptomatic or 
asymptomatic. If untreated, or inappropriately treated, the 
infection may result in severe complications, including 
genital and reproductive tract inflammation and damage, 
and infertility. Infection in pregnant women may lead to 
infections in the new-born, including eye infections which 
could cause blindness.  
In 2008, the WHO estimated there were 106 million new 
cases of gonorrhoea in adults aged 15–49 years globally. 
Tapsall JW et al (2009) state that globally, antimicrobial 
resistance (AMR) in Neisseria gonorrhoeae is increasing in 
prevalence, both within and across antibiotic classes, 
including extended-spectrum cephalosporins, raising 
concerns that gonorrhea may become untreatable in certain 
circumstances. The AMR-surveillance that is essential in 
optimizing standard treatments is frequently lacking or of 
poor quality in countries with high disease-rates although 
there is recent initiatives by the WHO to enhance global 
AMR-surveillance that focus on multidrug- and extensively 
drug-resistant N. gonorrhoeae through newer surveillance-
standards. Keys to meeting these new problems caused by 
gonococcal AMR are the reduction in global-burden of 
gonorrhea combined with implementation of wider-
strategies for general AMR-control, and better 
Meer Ahmad et al                                                                                                    Journal of Drug Delivery & Therapeutics. 2019; 9(2):534-541     
ISSN: 2250-1177                                                                                  [537]                                                                                 CODEN (USA): JDDTAO 
understanding of mechanisms in emergence and spread of 
AMR. 
Ohnishi M et al (2011) reported when the first Neisseria 
gonorrhoeae strain (H041), that is highly resistant to the 
extended-spectrum cephalosporin (ESC) ceftriaxone the last 
remaining option for empirical first-line treatment, was 
isolated. Detailed characterization of H041 was performed, 
phenotypically and genetically, to confirm the finding, 
examine its antimicrobial resistance (AMR), and elucidate 
the resistance mechanisms. H041 proved very resistant to 
ceftriaxone (2 to 4 μg/ml, which is 4- to 8-fold higher than 
any previously described isolate) and every remaing 
cephalosporins, besides most different antimicrobials tested. 
A new penA mosaic-allele was found to cause the 
ceftriaxone-resistance. Ohnishi et al conclude that N. 
gonorrhoeae has now shown its ability to also develop 
ceftriaxone resistance. The researchers belief N. 
gonorrhoeae may soon become a true superbug, causing 
untreatable gonorrhea – that which is required is a reduction 
in the global gonorrhea burden by enhanced disease control 
activities, combined with wider strategies for general AMR-
control and enhanced-understanding of the mechanisms of 
emergence and spread of AMR which need to be monitored 
globally, and public health response plans for global (and 
national) situations, besides the development of new drugs 
for efficacious gonorrhea-treatment. 
Lahra MM et al (2013) report on the Western Pacific region, 
which is densely populated with many living in poverty and 
with high-rates of infectious-diseases, a disproportionate-
burden of gonococcal disease and uncontrolled 
antimicrobial-use, which are recognized as ideal conditions 
for the emergence of AMR. The authors report that there is 
widespread, high-level resistance to penicillin and 
ciprofloxacin. Decreased susceptibility to ceftriaxone (MIC ≥ 
0.06 mg/L) is reported in high-levels from some countries in 
the region. Low numbers of isolates tested in some countries 
reflect capacity for testing which are suboptimal for 
surveillance. The emergence and spread of ceftriaxone-
resistant strains regionally is found alarming. Sustaining and 
enhancing surveillance is felt critical but obtaining an 
adequate sample-size was found a long-standing problem. 
The implementation of molecular-surveillance strategies is 
felt to possibly provide broader data on the spread and 
threat of AMR. 
Summary: Public health implications of N. gonorrheae 
resistance to third generation cephalosporins 
Emerging resistance has created obstacles in the treatment 
and control of gonorrhoea, in both resource-constrained and 
good-income countries.  
Due to widespread resistance, older and cheaper 
antibacterial drugs can no longer be used in treatment 
regimens. Treatment-failures with a third-generation 
cephalosporin (cefoxime) have been noted in many parts of 
the world. Yet, data from most countries around the world 
on the resistance is still lacking. 
 
 
Figure 1: Sources of data on Neisseria gonorrhea: decreased susceptibility to third-generation cephalosporins 
 
It is predicted that gonococci will become fully-resistant to 
the third-generation cephalosporins globally – and 
consequently, could result in becoming untreatable. 
Neonatal-infections and disseminated gonococcal-infections 
could be expected to become much more common, as in the 
era prior to antibacterial-treatment becoming existent. 
In aiming to facilitate effective-actions against the spread of 
multidrug-resistant N. gonorrhoeae, the WHO launched the 
Global Action Plan to Control the Spread and Impact of 
Antimicrobial Resistance in Neisseria gonorrhoeae in 2012. 
ANTIBIOTIC-RESISTANCE IN DISEASE-SPECIFIC 
PROGRAMMES 
Tuberculosis 
Globally, 3.6% of new TB cases and 20.2% of previously-
treated cases are estimated to be multidrug-resistant TB 
(MDR-TB), with much bigger-rates in Eastern Europe and 
Central Asia.  
Despite recent advancements in the diagnosis and treatment 
of MDR-TB, under-reporting of MDR-TB is extensive. 
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Treatment-success in MDR-TB is low, and is lower still in 
Extensively Drug-resistant (XDR-TB) cases. 
Gangneux S et al (2000) in using mathematical models 
predict that the future of the multidrug-resistant 
tuberculosis epidemic will depend on the fitness cost of drug 
resistance. The researchers showed that in laboratory-
derived mutants of Mycobacterium tuberculosis, rifampin 
resistance is universally associated with a competitive 
fitness-cost and that this cost is determined by the specific-
resistance mutation and strain genetic-background. In 
contrast, prolonged patient-treatment resulted in multi-drug 
resistant-strains with no fitness defect and that strains with 
low- or no-cost resistance mutations are also the most 
frequent among clinical isolates. 
Gillespie SH (2002) states that treatment with globally-
approved regimens results in a very high cure-rate with few 
relapses and without the emergence of resistance. These 
regimens are effective in preventing the emergence of 
resistance because combination-chemotherapy makes it 
highly unlikely that there will be a spontaneous-mutant 
resistant to all of the components of chemotherapy. Patients 
with uncomplicated-tuberculosis who receive inadequate 
treatment provide a selection-advantage for resistant-
mutants since bacteria may be exposed to monotherapy, 
permitting the emergence of resistance to single-agents and 
then to multiple-agents as the protection of combination-
chemotherapy becomes eroded. Clinical-complications such 
as empyema and extensive-cavitation permit a big 
population to develop in a compartment to which drugs may 
not penetrate. This large bacterial-pool increases the 
population for mutation, and with poor-penetration there is 
an increased-likelihood of resistance emerging. A similar 
situation may develop in patients with extensive disease or 
poor immunity. 
Gillespie states that resistant organisms over time will be 
fully virulent and that where an epidemic of multiple-drug-
resistant tuberculosis is to be prevented, every step must be 
taken to ensure that all patients are diagnosed and 
effectively treated such that resistant-strains are not created 
and transmitted in the community. 
Malaria 
Surveillance of antimalarial drug-efficacy is very necessary 
in the early-detection of antimalarial-drug resistance since 
resistance cannot be detected with routine laboratory-
procedures. 
Areas of suspected or confirmed artemisinin-resistance have 
been identified. Spread of such could jeopardize precious 
recent-gains in malaria-control. 
White NJ (2004) had stated that resistance has emerged to 
all classes of antimalarial drugs except the artemisinins and 
such was responsible for a recent increase in malaria-related 
mortality, particularly in Africa. The de novo emergence of 
resistance can be prevented by the use of antimalarial drug-
combinations. Artemisinin-derivative combinations are 
particularly effective, since they act rapidly and are better-
tolerated and very effective.  
HIV 
HIV drug-resistance is a clear cause of failure to achieve 
suppression of viral-replication, and thus causing increased-
risk for disease-progression. 
 Data collected between 2004 and 2010 in low- and middle-
income countries shows increasing levels of transmitted 
anti-HIV drug-resistance in patients being started with 
antiretroviral treatment (ART). 
Tang MW and Shafer RW (2012) state that the efficacy of an 
antiretroviral (ARV) treatment regimen depends on the 
activity of the regimen’s individual ARV-drugs and the 
number of HIV-1 mutations required for the development of 
resistance to each ARV — the genetic-barrier to resistance. 
ARV-resistance impairs the response to therapy in patients 
with transmitted-resistance, unsuccessful initial ARV-
therapy and multiple virological-failures. In patients with 
transmitted drug-resistance, the virological-response to a 
regimen selected on the basis of standard genotypic-testing, 
approaches the responses observed in patients with wild-
type viruses. But, since such patients are at a bigger risk of 
harbouring minority drug-resistant variants, initial ARV 
therapy in this population should contain a boosted protease 
inhibitor (PI) — the drug class with the highest genetic 
barrier to resistance. 
In patients receiving an initial ARV-regimen with a high 
genetic-barrier to resistance, the most common reasons for 
virological-failure are non-adherence and, potentially, 
pharmacokinetic-factors or minority-transmitted drug-
resistant variants. Among patients in whom first-line ARVs 
have failed, the patterns of drug-resistance mutations and 
cross-resistance are often predictable, but the extent of drug-
resistance correlates with the duration of uncontrolled 
virological-replication.  
Second-line therapy should include the continued use of a 
dual nucleoside/nucleotide reverse-transcriptase inhibitor 
(NRTI)-containing backbone, together with a change in the 
non-NRTI component, best to an ARV belonging to a new 
drug-class. 
A thorough examination of the patient’s ARV-history and 
prior resistance-tests should be performed since genotypic 
and/or phenotypic susceptibility-testing is frequently not 
sufficient to identify drug-resistant variants that emerged 
during past therapies and may still pose a threat to a new 
regimen. Phenotypic testing is also frequently helpful in this 
subset of patients. Understanding the basic principles of HIV 
drug-resistance is helpful in guiding individual clinical-
decisions and the development of ARV treatment-guidelines. 
Influenza 
There is very much resistance to adamantanes in circulating 
A (H1N1) and A (H3N2) viruses presently. 
In 2007/2008, there was emergence and rapid global-spread 
of oseltamivir-resistance in the former seasonal A (H1N1) 
viruses needing global antiviral-resistance surveillance. 
Van der Vries E et al (2013) identify antiviral drugs for 
influenza therapy and prophylaxis as either of the 
adamantane or neuraminidase inhibitor (NAI) class – but, 
the NAIs are mainly prescribed presently, due to widespread 
adamantane resistance involving influenza A viruses and 
ineffectiveness of adamantanes against influenza B. 
Emergence and spread of NAI resistance would further limit 
our therapeutic options. The authors postulate that taking 
into account the previous spread of oseltamivir-resistant 
viruses during the 2007/2008 season preceding the last 
pandemic, emergence of yet another naturally NAI-resistant 
influenza-virus may not be an unlikely event. The previous 
incident also underlines the importance of resistance-
surveillance and searches for a better-understanding of the 
mechanisms underlying primary-resistance development. A 
better-understanding of the effect of virus-mutations upon 
antiviral-treatment is called for along with a tailored 
antiviral-approach to severe influenza-virus infections. 
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Resistance in systemic candidiasis 
Systemic candidiasis is a common fungal-infection globally 
causing high rates of morbidity and mortality in certain 
groups of patients.  
The global burden of antifungal-resistant Candida is 
unknown.  Resistance to Fluconazole, and even the newest 
echinocandins, varies widely by country and species. 
Within the limited antifungal armamentarium, the azole-
antifungals are the most frequent class used to treat Candida 
infections. Azole antifungals such as fluconazole are 
frequently preferred treatment for many Candida infections 
and as such are inexpensive, exhibit limited toxicity, and are 
obtainable for oral administration. But, there is extensive 
documentation of intrinsic and developed resistance to 
azole-antifungals among several Candida species. As the 
frequency of azole-resistant Candida-isolates in the clinical-
setting increases, it is essential to elucidate the mechanisms 
of such resistance with the aim to both preserve and 
improve upon the azole-class of antifungals for the treatment 
of Candida infections, caused by C. albicans besides the 
emerging non-albicans Candida species C. parapsilosis, C. 
tropicalis, C. krusei, and C. glabrata. (Whaley SG et al 2016). 
Antibacterial resistance (ABR) in food-producing 
animals and the food chain 
Major needs exist still in surveillance and data-sharing 
related to the emergence of ABR in foodborne bacteria, and 
the potential impact of such on both animal and human 
health. 
A multi-sectoral approach is needed to contain ABR, and this 
has to include improved integrated-surveillance of ABR in 
food-producing animals and in the food chain. 
ANTIBIOTIC PRESCRIBING IN PUBLIC AND 
PRIVATE PRIMARY CARE CLINICS IN MALAYSIA 
Norazida AR et al (2016) in a study using nationwide data 
from 129 public clinics and 416 private clinics, showed that 
5810 encounters were prescribed antibiotics.  
Overall antibiotic-prescribing rate was 21.1 % - public clinics 
6.8 %, private clinics 30.8 %. 
Upper respiratory tract infection (URTI), which is primarily 
of viral-cause, was the most frequent diagnosis in patients 
receiving antibiotic therapy (49.2 % of prescriptions). Of the 
patients diagnosed with URTI, 46.2 % received antibiotic 
treatment (public 16.8 %, private 57.7 %), although they 
were mostly not indicated clinically. 
More recently available broad-spectrum antibiotics such as 
azithromycin and quinolones were more frequently 
prescribed in private clinics. 
They observed that excessive or suboptimal use of medicines 
in general, and antibiotics in particular, is a worldwide 
concern. A systematic review by the WHO of medicine-use in 
developing and transitional countries, has shown an 
increasing trend of antibiotics to 71% in the period 2004 – 
2006, which is higher than in the Malaysian scenario. 
But, when compared with more developed countries such as 
the Netherlands and Hong Kong, the antibiotic-prescribing 
rates in Malaysia are still a cause for concern.  
My own observation is that many private primary care 
clinics prescribe antibiotics for URTI, mostly to increase their 
profits from a larger bill. 
The newer broad-spectrum antibiotics are observed to be 
prescribed especially by newer clinics, and especially when 
insurance companies, MCO’s and panel-companies allow a 
larger bill per patient – these newer antibiotics are costlier, 
and thus allow a greater profit. 
It is my observation too that almost all retail-pharmacies 
dispense antibiotics without prescriptions – although 
antibiotics are classified Group-B poisons. 
Norazida AR et al conclude that their findings emphasize the 
need for more concerted interventions targeting both 
prescribers and the public, reducing inappropriate 
prescribing.  
We should all agree to that, in addition keeping dispensing 
by retail-pharmacists under surveillance. 
In Malaysia, national antibiotic guidelines were introduced in 
2008, and updated in 2014.  
However, they say that the current effort to improve 
antibiotic stewardship in Malaysia is still in the early-stages. 
The right type of sustainable-intervention needs to be 
implemented, such as academic-detailing by senior family 
physicians, and feedback of prescribing data to primary care 
doctors – and these interventions periodically evaluated. 
Continuing Medical Education for practicing doctors needs to 
highlight the ongoing problem of antibiotic overuse and the 
emergence of antibiotic resistance. 
Public-education of the harm of excessive antibiotic use is 
currently being carried out in Malaysia, but it needs to be 
persistent, they say. 
Tan WL et al (2015), concluded that knowledge on 
antibiotics among our Medical Officers in public health-care 
facilities was only moderate. 
They recommend more training and courses on appropriate 
antibiotic-prescribing to ensure the best-practice in 
antibiotic-prescription. 
Muhammad Qamar et al (2014), observed that only 43% of 
the general public in Shah Alam had good knowledge about 
antibiotics. 
And, 57.4% still expected antibiotic to be prescribed for 
common cold.  
The authors concluded that although the knowledge of the 
public was good, the importance of correct usage of 
antibiotic needed to be emphasized on them, and changes in 
their attitude towards antibiotic usage needed to be 
promoted.   
THE HEALTH AND ECONOMIC BURDEN DUE TO 
ANTIBACTERIAL RESISTANCE 
Whether antibiotic resistance poses a significant Health and 
Economic burden for patients and healthcare systems is a 
key question.  
To address this knowledge gap, systematic reviews were 
carried out for the WHO Report. 
Health burden 
Table 1 summarizes the Mortality, while Table 2, the 
Admissions
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Table 1: Mortality 
 All-cause 
mortality 
Bacterium-attributable 
mortality 
30-day 
mortality 
ICU mortality 
Third-gen cephalosprin-resistant E. coli infection Increase Increase Increase No data 
Fluoroquinolone-resistant E. coli infection Increase No increase Increase No data 
Third-gen cephalosporin-resistant K. 
pneumoniae infection 
 
Increase 
 
Increase 
 
Increase 
 
No data 
Carbenepem-resistant K. pneumoniae infection Increase No increase Increase No increase 
MRSA infection Increase Increase No increase Increase 
 
Table 2: Admissions 
 Length of Stay 
(LOS) 
ICU Admissions Incidence of 
Septic-shock 
Third-gen cephalosprin-resistant E. coli infection No increase No increase No data 
Fluoroquinolone-resistant E. coli infection No increase Increase Increase 
Third-gen cephalosporin-resistant K. pneumoniae infection No increase No increase No increase 
Carbenepem-resistant K. pneumoniae infection Increase Increase No data 
MRSA infection No increase No increase Increase 
 
Economic burden  
The cost impact of ABR has not been adequately measured. 
From the few, the conclusion was that all-costs for infections 
caused by resistant strains were consistently greater than 
those for infections caused by susceptible strains, with few 
exceptions. 
There are few studies reporting data on increased-cost 
associated with resistant E. coli and K. pneumoniae 
infections. One study from UK reported that the additional 
costs for urinary tract infections caused by resistant E. coli 
managed in general practice was £3.62. And in one 
remaining study from Thailand, the hospitalization costs 
increased to a median US$ 528 from US$ 108, in patients 
with ESBL-producing E. coli infections. 
A study in the USA in which Klebsiella spp and E. coli were 
included among other Gram-negative bacteria, reported that 
“patients infected with resistant bacteria had a median total 
hospital cost US$ 38, 121 higher than that for patients 
infected with susceptible bacteria (US$ 144,414 and 106,293 
respectively)”. 
The clinical trials for MRSA captured a few resource-use 
outcomes: there was a longer duration of both hospital 
(mean difference of 4.65 days) and ICU LOS (mean difference 
of 4.0 days) for patients with MRSA compared to those with 
MSSA. In addition, a higher proportion of patients with MRSA 
tended to be discharged from hospital to other care facilities 
(long-term care facility or other health-care facilities). 
Two reviews found that because costs of resistance are 
mainly measured in in-patients, the overall burden may be 
underestimated. 
Tumbarello M et al (2010) in a retrospective 1-year analysis 
of 134 consecutive E. coli blood-stream infections (BSIs) in a 
hospital, explored the clinical and economic impacts of (i) 
inadequate initial antimicrobial treatment (IIAT) (i.e., 
empirical treatment with drugs to which the isolate had 
displayed in vitro resistance) of these infections and (ii) 
ESBL-production by the bloodstream-isolate. Compared with 
the 107 (79.8%) adequately treated patients, the 27 (20.1%) 
who received IIAT had a higher proportion of ESBL BSIs 
(74.0% versus 15.8%), longer (+6 days) and more costly 
(+EUR 4,322.00) post-BSI-onset hospital stays, and increased 
21-day mortality rates (40.7% versus 5.6%). Compared with 
the 97 non-ESBL infections, the 37 (27.6%) ESBL BSIs were 
also associated with longer (+7 days) and more costly (+EUR 
5,026.00) post-BSI-onset hospital stays and increased 21-day 
mortality (29.7% versus 6.1%).  
These findings confirm that the hospital costs and mortality 
associated with E. coli BSIs are significantly increased by 
ESBL production and by IIAT. 
Naylor NR et al (2018) in a systematic review showed that 
48% of studies estimating mortality burden found a 
significant impact from antibiotic-resistance - excess 
healthcare system costs ranged from non-significance to $1 
billion per year, whilst economic burden ranged from 
$21,832 per case to over $3 trillion in GDP loss.  
Woolhouse N et al (2016) in a review state that information 
presently collected at global or multi–national scales is not 
sufficient to generate estimates of the disease burden 
attributable to antibiotic resistance. As a result, present 
knowledge of the burden of antibiotic resistance is still based 
largely on the collation of one–off, small–scale, individual 
studies that vary greatly in setting, scope, sampling frame 
and methodology, and often requires bold extrapolations to 
be made from very limited data sets. For estimation of the 
global burden of antibiotic resistance and, even more, for 
monitoring changes in burden over time more systematic 
approaches would be helpful. There are several possibilities 
the researchers state that ICD–11 replacing ICD–10 in 2017 
provides an opportunity to create routinely used categories 
that record treatment failures, or at least linking treatments 
with outcomes, the most direct ways to estimate the burden 
of antibiotic resistance. Specific concerns, such as XDR–TB or 
carbapenem–resistant Enterobacteriaceae, might be 
prioritised for inclusion. 
The researchers also state that ICD facilitates passive 
reporting. One version could be active reporting by 
recruiting sentinel sites. For example, 660 hospitals from 67 
countries responded to an internet survey on antimicrobial 
stewardship in 2012. Monitoring treatment failures due to 
antibiotic resistance in these hospitals using standardised 
protocols would generate valuable data, it is felt. Making 
selected, high priority antibiotic resistant infections 
‘notifiable’ at national level could further improve data 
capture, extending existing mandatory-reporting for specific 
conditions (for example in the UK for scarlet fever or 
invasive streptococcal group A disease). Another possibility 
is a more qualitative approach of recruiting a global panel of 
individual clinicians who are polled (proved successful 
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previously in different clinical-context) to determine trends 
in the impact of antibiotic resistance on their patients. 
Besides estimating the global burden of antibiotic resistance 
an additional useful exercise would be to estimate the global-
burden due to lack of access to suitable antibiotics. The two 
matters potentially overlap where there is a lack of 
knowledge of local resistance profiles (perhaps due to lack of 
testing facilities) and that alternative drugs would have been 
effective. 
Knowledge-gap 
Based on the current ﬁndings, the following gaps need to be 
addressed: 
1. standardization and implementation of a minimum data 
set;  
2. evaluation of both clinical outcomes and resource use in 
high-quality studies; 
3. evaluation of health and economic burden in a broader 
array of settings – including low- and low–middle-
income countries; and 
4. The need for improved models, besides recent ones, to 
assess economic impact on health-care systems and 
society. 
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